Development and characterization of Glibenclamide containing Transdermal Patches

  • Syed Ata Ur Rahman
  • Neeraj Sharma


Transdermal drug delivery has had a rich past and is now emerging as a major alternative to other delivery systems. As this technique has matured and new fundamentals have been integrated into its development, new products and applications have shown new ways in which skin can play a larger part in healthcare and quality of life. Improved delivery has been shown for drugs of differing. The cumulative percentage of drug released in 12 h was found to be minimum and maximum for the formulations F4 and F10 i.e. 81.023 ± 3.013 % and 98.564 ±3.005%.The results of the drug content in all the formulations were found to be in the range of 96 to 98 %. The maximum moisture loss was 4.3300 ± 0.0360 %. The prepared film had tendency to absorb moisture effectively. Glibenclamide is a third generation oral anti-diabetic sulphonylurea drug frequently prescribed to patients of type 2 diabetes. Glibenclamide therapy improves postprandial insulin/C-peptide response, and overall glycaemia control. The development of Glibenclamide transdermal patch for anti-diabetic will be an excellent dosage form for market strategy due to its very fast action and better patient compliance.

Keywords: Transdermal, cyclodextrin, formulation, release


Download data is not yet available.


1. Alotaibi MR, Fatani AJ, Almnaizel AT, Ahmed MM, Abuohashish HM, Al-Rejaie SS. In vivo Assessment of Combined Effects of Glibenclamide and Losartan in Diabetic Rats. Med Princ Pract 2019; 28(2):178–89.
2. Balsells M, García-Patterson A, Solà I, Roqué M, Gich I, Corcoy R. Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: A systematic review and meta-analysis. Obstet Gynecol Surv 2015; 350:1–12.
3. Dubey S, Ganeshpurkar A, Bansal D, Dubey N. Protective effect of rutin on cognitive impairment caused by phenytoin. Indian J Pharmacol 2015; 47(6):627–31.
4. Ganeshpurkar A, Saluja AK. Protective effect of rutin on humoral and cell mediated immunity in rat model. Chem Biol Interact 2017;273.
5. Ganeshpurkar A, Saluja AK. The Pharmacological Potential of Rutin. Saudi Pharm. J.2017; 25(2):149–64.
6. Diwan V, Srinivasa TS, Ramreddy KY, Agrawal V, Nagdeve S, Parvez H. A comparative evaluation of transdermal diclofenac patch with oral diclofenac sodium as an analgesic drug following periodontal flap surgery: A randomized controlled clinical study. Indian J Dent Res 2019; 30(1):57.
7. Chourasia S, Shukla T, Dangi S, Upmanyu N, Jain N. Formulation and evaluation of matrix transdermal patches of meloxicam. J Drug Deliv Ther 2019; 9(1–s):209–13.
8. Ameen D, Michniak-Kohn B. Development and In vitro evaluation of Pressure Sensitive Adhesive Patch for the Transdermal Delivery of Galantamine: Effect of Penetration Enhancers and Crystallization Inhibition. Eur J Pharm Biopharm 2019;
9. Shirodker A, Gude R, Vaidya S, Bhangle S, Parab S, Gadi N, et al. Fabrication and characterization of a matrix-type transdermal patch containing microspheres of risperidone. Int J Res Pharm Sci 2019; 10(1):45–9.
10. Kulkarni S. Formulation and Evaluation of Transdermal Patch for Atomoxetine hydrochloride. J Drug Deliv Ther 2019;9(2–A):32–5.
11. Liao S, Liu H, Zhao J, Wang Y, Guo Z. Optimization of Phencynonate Hydrochloride Transdermal Patch Formulation by Box-Behnken Design-response Surface Methodology. China Pharm 2018; 29(7):897–901.
12. Ganeshpurkar A, Vaishya P, Jain S, Pandey V, Bansal D, Dubey N. Delivery of amphotericin B for effective treatment of Candida albicans induced dermal mycosis in rats via emulgel system: Formulation and evaluation. Indian J Dermatol 2014; 59(4):369–74.
13. Pandey V, Vishawkarma N, Ganeshpurkar A, Dubey N, Bansal D. Eudragit coated pectin microsphere of Aminophylline for colonic delivery. Asian J Biomater Res 2015; 1(1):17–22.
17 Views | 34 Downloads
How to Cite
Rahman, S. A. U., & Sharma, N. (2019). Development and characterization of Glibenclamide containing Transdermal Patches. Journal of Drug Delivery and Therapeutics, 9(3), 427-429.